Get the Stockscreener App
7.63
2.01%
0.15
Eyepoint Pharmaceuticals Inc stock is traded at $7.63, with a volume of 490.50K.
It is up +2.01% in the last 24 hours and up +7.46% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$7.48
Open:
$7.65
24h Volume:
490.50K
Relative Volume:
0.53
Market Cap:
$520.76M
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-4.1923
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+5.97%
1M Performance:
+7.46%
6M Performance:
-13.30%
1Y Performance:
-65.82%
1-Day Range:
$7.36
$7.73
1-Week Range:
$7.15
$8.25
52-Week Range:
$6.90
$30.99
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
7.63 | 520.76M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Up 9.9% in December - MarketBeat
JPMorgan Chase & Co. Purchases 342,516 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
JPMorgan Chase & Co. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 3.4%Here's What Happened - MarketBeat
There Is A Lot Of Upside Potential For EyePoint Pharmaceuticals Inc(NASDAQ: EYPT) - Stocks Register
Further weakness as EyePoint Pharmaceuticals (NASDAQ:EYPT) drops 20% this week, taking one-year losses to 68% - Simply Wall St
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
EyePoint Pharmaceuticals Awards Stock Options to New Employees in Retention Move - StockTitan
(EYPT) Trading Signals - Stock Traders Daily
EyePoint reports progress in DURAVYU AMD trials By Investing.com - Investing.com Canada
EyePoint reports progress in DURAVYU AMD trials - Investing.com India
EYPTEyePoint Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
EyePoint's DURAVYU Shows Strong DME Trial Results, Reports $370M Cash Position for 2025 - StockTitan
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of “Buy” from Analysts - Defense World
Brokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $26.63 - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.8%Here's What Happened - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Research Coverage Started at Citigroup - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Jane Street Group LLC - Defense World
EyePoint Pharmaceuticals expands board with key appointment - Investing.com
EyePoint Pharmaceuticals Strengthens Board with New Appointment - TipRanks
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - The Manila Times
EyePoint Strengthens Board with Leading Retina Specialist Dr. Sanders Amid Clinical Trial Progress - StockTitan
Citigroup Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy Recommendation - MSN
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
EyePoint initiated at buy by Citi on wAMD drug potential (EYPT:NASDAQ) - Seeking Alpha
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap UpHere's What Happened - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at Citigroup - MarketBeat
Citi initiates Buy rating on EyePoint stock with promising wAMD prospects - Investing.com Nigeria
EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6%Here's What Happened - MarketBeat
(EYPT) Trading Advice - Stock Traders Daily
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Geode Capital Management LLC - Defense World
Geode Capital Management LLC Has $9.58 Million Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 5.8%Should You Buy? - MarketBeat
Certain Common Stock of EyePoint Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2024. - Marketscreener.com
EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference - Marketscreener.com
Barclays PLC Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Barclays PLC Has $1.96 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
State Street Corp Has $9.72 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
How the (EYPT) price action is used to our Advantage - Stock Traders Daily
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
Franklin Resources Inc. Raises Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 6.4% in November - Defense World
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4%Here's Why - MarketBeat
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
EyePoint reports inducement grants under NASDAQ listing rule - Yahoo Finance
EyePoint Pharmaceuticals to Present at JP Morgan Healthcare Conference 2025 - StockTitan
EYPT stock touches 52-week low at $7.4 amid market challenges - Investing.com Canada
Short Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4% - MarketBeat
EyePoint Pharmaceuticals (NASDAQ:EYPT) Sets New 52-Week LowHere's Why - MarketBeat
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):